

# **HOUSE BILL No. 1349**

DIGEST OF HB 1349 (Updated January 29, 2007 1:00 pm - DI 77)

Citations Affected: IC 25-24; IC 35-48.

**Synopsis:** Legend drug prescriptions by optometrists. Allows optometrists who are certified by the optometric board to administer, dispense, and prescribe certain narcotic drugs, codeine with compounds, and hydrocodone with compounds. Repeals a law concerning drug formulary requirements. Adds an optometrist to the controlled substances advisory committee. Makes conforming changes.

Effective: July 1, 2007.

# Welch, Frizzell, Reske, Hoy

January 16, 2007, read first time and referred to Committee on Public Health. January 30, 2007, reported — Do Pass.





### First Regular Session 115th General Assembly (2007)

PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in this style type, and deletions will appear in this style type.

Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in this style type. Also, the word **NEW** will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.

Conflict reconciliation: Text in a statute in this style type or this style type reconciles conflicts between statutes enacted by the 2006 Regular Session of the General Assembly.

## **HOUSE BILL No. 1349**

A BILL FOR AN ACT to amend the Indiana Code concerning professions and occupations.

Be it enacted by the General Assembly of the State of Indiana:

	7
11	

1	SECTION 1. IC 25-24-3-6, AS ADDED BY P.L.157-2006,
2	SECTION 65, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
3	JULY 1, 2007]: Sec. 6. (a) As used in this chapter, "legend drug" has
4	the meaning set forth in IC 16-18-2-199. The term includes a narcotic
5	drug listed under IC 35-48-2-8(e), codeine with compounds, and
6	hydrocodone with compounds.
7	(b) Subject to subsection (a), the term does not include:

- (b) Subject to subsection (a), the term does not include:
  - (1) a schedule I controlled substance substance (as defined in <del>IC 35-48-1-9).</del> **IC 35-48-2-4)**;
  - (2) a schedule II controlled substance (as defined in IC 35-48-2-6); or
- (3) a schedule III controlled substance listed in IC 35-48-2-8(a) through IC 35-48-2-8(d) and IC 35-48-2-8(f) through IC 35-48-2-8(h).
- SECTION 2. IC 25-24-3-10, AS ADDED BY P.L.157-2006, SECTION 65, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE

17 JULY 1, 2007]: Sec. 10. The board shall do the following:



8

9

10

11 12

13 14

15

16

HB 1349—LS 7432/DI 77+





1	(1) Adopt rules under IC 4-22-2 to do the following:
2	(A) Establish a formulary of legend drugs that may be
3	prescribed, dispensed, or administered by an optometrist.
4	(B) Set fees described in IC 25-1-8.
5	(C) Carry out this chapter.
6	(2) Except for a drug listed in subdivision (3), establish
7	education and training requirements in ocular pharmacology
8	required for certification to do the following:
9	(A) Administer therapeutic legend drugs.
10	(B) Dispense legend drugs.
11	(C) Prescribe legend drugs.
12	(3) Establish education and training requirements required
13	for certification to administer, dispense, or prescribe a
14	narcotic drug listed in IC 35-48-2-8(e), codeine with
15	compounds, and hydrocodone with compounds.
16	(3) (4) Establish continuing education requirements for renewal
17	of the certificate issued under this chapter.
18	SECTION 3. IC 25-24-3-12, AS ADDED BY P.L.157-2006,
19	SECTION 65, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
20	JULY 1, 2007]: Sec. 12. (a) The board shall issue a an optometric
21	legend drug certificate to a licensed optometrist who:
22	(1) applies; and
23	(2) successfully fulfills all the requirements of section 10(2) of
24	this chapter.
25	(b) The board shall issue an optometric controlled substance
26	certificate to a licensed optometrist who:
27	(1) applies; and
28	(2) successfully fulfills the requirements of section 10(3) of this
29	chapter.
30	SECTION 4. IC 25-24-3-16, AS ADDED BY P.L.157-2006,
31	SECTION 65, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
32	JULY 1, 2007]: Sec. 16. (a) Optometrists may administer topical
33	diagnostic legend drugs limited to:
34	(1) miotics;
35	(2) mydriatics;
36	(3) anesthetics; and
37	(4) cycloplegics;
38	without holding a certificate issued under this chapter. These
39	pharmaceutical agents may be applied in diagnostic procedures only as
40	a part of an examination of the eye.
41	(b) The board may authorize an optometrist holding a certificate
42	issued under section 12(a) of this chapter to:



1	(1) administer for therapeutic use;
2	(2) dispense; or
3	(3) prescribe;
4	legend drugs that are included in the formulary established by the
5	board under section 10 of this chapter, in the treatment of any condition
6	of the eye or the associated structures of the eye.
7	(c) The board may authorize an optometrist holding a certificate
8	issued under section 12(b) of this chapter to:
9	(1) administer for therapeutic use;
10	(2) dispense; or
11	(3) prescribe;
12	codeine with compounds, hydrocodone with compounds, and
13	narcotic drugs listed under IC 35-48-2-8(e) that are included in the
14	formulary established by the board under section 10 of this
15	chapter, in the treatment of any condition of the eye or the
16	associated structures of the eye.
17	SECTION 5. IC 25-24-3-17, AS ADDED BY P.L.157-2006,
18	SECTION 65, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
19	JULY 1, 2007]: Sec. 17. (a) An optometrist may not:
20	(1) administer, dispense, or prescribe therapeutic legend drugs; or
21	(2) dispense or prescribe diagnostic legend drugs, narcotic drugs
22	listed under IC 35-48-2-8(e), codeine with compounds, or
23	hydrocodone with compounds;
24	unless the optometrist is certified under this chapter.
25	(b) An optometrist may not prescribe or dispense for a patient
26	more than a five (5) day supply of:
27	(1) a narcotic drug listed under IC 35-48-2-8(e);
28	(2) codeine with compounds; or
29	(3) hydrocodone with compounds.
30	(b) (c) An optometrist may administer diagnostic legend drugs
31	without obtaining a certificate under this chapter.
32	(c) (d) An individual who recklessly, knowingly, or intentionally
33	violates this chapter commits a Class A misdemeanor.
34	SECTION 6. IC 35-48-2-1 IS AMENDED TO READ AS
35	FOLLOWS [EFFECTIVE JULY 1, 2007]: Sec. 1. (a) The board shall
36	administer this article and may recommend to the general assembly the
37	addition, deletion, or rescheduling of all substances listed in the
38	schedules in sections 4, 6, 8, 10, and 12 of this chapter by submitting
39	in an electronic format under IC 5-14-6 a report of such
40	recommendations to the legislative council. In making a determination
41	regarding a substance, the board shall consider the following:



42

(1) The actual or relative potential for abuse.

1	(2) The scientific evidence of its pharmacological effect, if
2	known.
3	(3) The state of current scientific knowledge regarding the
4	substance.
5	(4) The history and current pattern of abuse.
6	(5) The scope, duration, and significance of abuse.
7	(6) The risk to public health.
8	(7) The potential of the substance to produce psychic or
9	physiological dependence liability.
10	(8) Whether the substance is an immediate precursor of a
11	substance already controlled under this article.
12	(b) After considering the factors enumerated in subsection (a), the
13	board shall make findings and recommendations concerning the control
14	of the substance if it finds the substance has a potential for abuse.
15	(c) If the board finds that a substance is an immediate precursor,
16	substances which are precursors of the controlled precursor shall not
17	be subject to control solely because they are precursors of the
18	controlled precursor.
19	(d) If any substance is designated or rescheduled to a more
20	restrictive schedule as a controlled substance under federal law and
21	notice is given to the board, the board shall recommend similar control
22	of the substance under this article in the board's report to the general
23	assembly, unless the board objects to inclusion or rescheduling. In that
24	case, the board shall publish the reasons for objection and afford all
25	interested parties an opportunity to be heard. At the conclusion of the
26	hearing, the board shall publish its findings.
27	(e) If a substance is rescheduled to a less restrictive schedule or
28	deleted as a controlled substance under federal law, the substance is
29	rescheduled or deleted under this article. If the board objects to
30	inclusion, rescheduling, or deletion of the substance, the board shall
31	notify the chairman of the legislative council not more than thirty (30)
32	days after the federal law is changed and the substance may not be
33	rescheduled or deleted until the conclusion of the next complete
34	session of the general assembly. The notice from the board to the
35	chairman of the legislative council must be published.
36	(f) There is established a sixteen (16) seventeen (17) member
37	controlled substances advisory committee to serve as a consultative and
38	advising body to the board in all matters relating to the classification,
39	reclassification, addition to, or deletion from of all substances
40	classified as controlled substances in schedules I to IV or substances

not controlled or yet to come into being. In addition, the advisory

committee shall conduct hearings and make recommendations to the



41 42

1	board regarding revocations, suspensions, and restrictions of
2	registrations as provided in IC 35-48-3-4. All hearings shall be
3	conducted in accordance with IC 4-21.5-3. The advisory committee
4	shall be made up of:
5	(1) two (2) physicians licensed under IC 25-22.5, one (1) to be
6	elected by the medical licensing board of Indiana from among its
7	members and one (1) to be appointed by the governor;
8	(2) two (2) pharmacists, one (1) to be elected by the state board
9	of pharmacy from among its members and one (1) to be appointed
10	by the governor;
11	(3) two (2) dentists, one (1) to be elected by the state board of
12	dentistry from among its members and one (1) to be appointed by
13	the governor;
14	(4) the state toxicologist or the designee of the state toxicologist;
15	(5) two (2) veterinarians, one (1) to be elected by the state board
16	of veterinary medical examiners from among its members and one
17	(1) to be appointed by the governor;
18	(6) one (1) podiatrist to be elected by the board of podiatric
19	medicine from among its members;
20	(7) one (1) advanced practice nurse with authority to prescribe
21	legend drugs as provided by IC 25-23-1-19.5 who is:
22	(A) elected by the state board of nursing from among the
23	board's members; or
24	(B) if a board member does not meet the requirements under
25	IC 25-23-1-19.5 at the time of the vacancy on the advisory
26	committee, appointed by the governor;
27	(8) the superintendent of the state police department or the
28	superintendent's designee;
29	(9) three (3) members appointed by the governor who have
30	demonstrated expertise concerning controlled substances; and
31	(10) one (1) member appointed by the governor who is a
32	psychiatrist with expertise in child and adolescent psychiatry; and
33	(11) one (1) optometrist to be elected by the Indiana
34	optometry board from among its members.
35	(g) All members of the advisory committee elected by a board shall
36	serve a term of one (1) year and all members of the advisory committee
37	appointed by the governor shall serve a term of four (4) years. Any
38	elected or appointed member of the advisory committee, may be
39 40	removed for cause by the authority electing or appointing the member.
40	If a vacancy occurs on the advisory committee, the authority electing or appointing the vacating member shall elect or appoint a successor to
41	or appointing the vacating member shall elect or appoint a successor to

serve the unexpired term of the vacating member. The board shall



42

1	acquire the recommendations of the advisory committee pursuant to
2	administration over the controlled substances to be or not to be
3	included in schedules I to V, especially in the implementation of
4	scheduled substances changes as provided in subsection (d).
5	(h) Authority to control under this section does not extend to
6	distilled spirits, wine, or malt beverages, as those terms are defined or
7	used in IC 7.1, or to tobacco.
8	(i) The board shall exclude any nonnarcotic substance from a
9	schedule if that substance may, under the Federal Food, Drug, and
10	Cosmetic Act or state law, be sold over the counter without a
11	prescription.
12	SECTION 7. IC 35-48-2-1.5, AS AMENDED BY P.L.1-2006,
13	SECTION 546, IS AMENDED TO READ AS FOLLOWS
14	[EFFECTIVE JULY 1, 2007]: Sec. 1.5. (a) The advisory committee
15	shall annually elect a chairperson and any other officers that the
16	advisory committee determines necessary from among its members.
17	(b) Meetings of the advisory committee may be called by:
18	(1) the advisory committee chairperson; or
19	(2) a majority of the members of the advisory committee.
20	(c) Seven (7) Nine (9) members of the advisory committee
21	constitute a quorum.
22	(d) Notwithstanding IC 1-1-4-1, if at least a quorum of its members
23	are present at a meeting, the <b>advisory</b> committee may take an action by
24	an affirmative vote of at least a majority of the members present and
25	voting.
26	(e) The advisory committee shall adopt rules under IC 4-22-2 to:
27	(1) set standards related to the registration and control of the
28	manufacture, distribution, and dispensing of controlled
29	substances, including record keeping requirements;
30	(2) set fees described in IC 25-1-8; and
31	(3) carry out its responsibilities under IC 35-48-2 through
32	IC 35-48-3.
33	(f) The Indiana professional licensing agency shall provide staff and
34	facilities to the advisory committee under IC 25-1-5.
35	(g) Each member of the advisory committee who is not a state
36	employee is entitled to the minimum salary per diem provided by
37	IC 4-10-11-2.1(b). Such a The member is also entitled to
38	reimbursement for traveling expenses and other expenses actually
39	incurred in connection with the member's duties, as provided in the
40	state travel policies and procedures established by the department of
41	administration and approved by the budget agency.

(h) Each member of the advisory committee who is a state



42

1	employee is entitled to reimbursement for traveling expenses and other
2	expenses actually incurred in connection with the member's duties, as
3	provided in the state travel policies and procedures established by the
4	department of administration and approved by the budget agency.
5	SECTION 8. IC 25-24-3-11 IS REPEALED [EFFECTIVE JULY 1,
6	20071

C o p



### COMMITTEE REPORT

Mr. Speaker: Your Committee on Public Health, to which was referred House Bill 1349, has had the same under consideration and begs leave to report the same back to the House with the recommendation that said bill do pass.

BROWN C, Chair

Committee Vote: yeas 8, nays 3.

C

O

p

y

